Is Gabapentin a Pain Reliever? Uses and Side Effects

Gabapentin isn’t a traditional painkiller, but it does relieve certain types of pain. Learn what it treats, how it works, and what side effects to expect.

Gabapentin relieves pain, but not the way most people assume. It does nothing for a typical headache or a sprained ankle. Instead, it targets nerve-related pain by acting on calcium channels in the nervous system, which makes it effective for conditions like the burning, shooting pain that follows shingles or accompanies diabetic nerve damage. Classified as an anticonvulsant (it was originally developed for epilepsy), gabapentin has become one of the most widely prescribed drugs in the United States, with the majority of its use now falling outside its original seizure indication.

How Gabapentin Works Against Pain

Gabapentin does not work like ibuprofen, acetaminophen, or opioids. Those drugs target inflammation, fever pathways, or opioid receptors. Gabapentin instead binds to a specific protein on nerve cells called the alpha-2-delta-1 subunit of voltage-gated calcium channels. By latching onto this subunit, it dials down the release of chemical signals that amplify pain in the nervous system. This interaction is consistently seen in both animal models and human studies, and most researchers consider it the primary explanation for the drug’s pain-relieving effects.

The interesting wrinkle is that gabapentin’s pain relief seems to depend on the nervous system already being in an abnormal state. In healthy nerve tissue, gabapentin does not consistently reduce pain signaling. After nerve injury, however, the alpha-2-delta-1 subunit gets overproduced in damaged nerve cells, and that overproduction appears to be what gabapentin capitalizes on. This is why gabapentin helps with nerve pain but often fails for ordinary aches and pains where the nerves themselves are not damaged.

FDA-Approved Uses for Pain

Gabapentin carries two pain-related approvals from the U.S. Food and Drug Administration, both for types of neuropathic pain.

Postherpetic Neuralgia

Postherpetic neuralgia is the persistent burning or stabbing pain that can linger for months or years after a shingles outbreak. It is one of the most common forms of nerve pain in older adults, and it was the first pain condition gabapentin was approved to treat. In a landmark randomized trial, patients taking gabapentin saw their average daily pain score drop by about a third, compared with less than an 8% drop in the placebo group. Extended-release versions of gabapentin, designed to be taken once or twice daily instead of three times, have also shown meaningful reductions in pain, with roughly a quarter to a third of patients in trials achieving at least a 50% decrease in their pain scores.

Diabetic Peripheral Neuropathy

Nerve damage from diabetes often produces pain, numbness, or tingling in the feet and hands. A randomized controlled trial found that gabapentin reduced average daily pain scores from roughly 6.4 to 3.9 on a 10-point scale, significantly outperforming placebo, and also improved quality-of-life measures. A head-to-head comparison with amitriptyline, an older antidepressant commonly used for nerve pain, found no significant difference in pain relief between the two drugs, suggesting gabapentin is a reasonable alternative for patients who cannot tolerate antidepressants or their side effects. Extended-release gabapentin taken once daily has similarly shown benefit, with about 35% of patients achieving at least a 50% pain reduction versus under 8% on placebo.

Gabapentin’s Original Purpose Was Not Pain

Before it became synonymous with nerve pain treatment, gabapentin was approved as an add-on therapy for focal epilepsy. A Cochrane review pooling data from six trials found that people taking gabapentin were roughly twice as likely to experience at least a 50% reduction in seizure frequency compared with placebo, with higher doses performing better. A separate trial comparing gabapentin directly with pregabalin for focal seizures found no significant difference between the two drugs. While seizure treatment remains an approved use, the vast majority of gabapentin prescriptions today are written for pain and other off-label purposes.

Off-Label Pain Uses and Where the Evidence Thins

Because gabapentin helped with nerve pain, clinicians began trying it for nearly every chronic pain condition they could think of. The results have been uneven.

Fibromyalgia

Fibromyalgia involves widespread pain that is not clearly tied to nerve damage, making it a less obvious fit for gabapentin. A single well-designed trial of 150 people found that about half of patients on gabapentin achieved at least a 30% pain reduction versus about a third on placebo, and far more reported feeling “better” overall. However, a Cochrane review concluded there is insufficient evidence to support or refute gabapentin for fibromyalgia because the data comes from just that one trial. That trial did find statistically significant improvements in average pain severity, sleep quality, and overall functioning in the gabapentin group. A meta-analysis that pooled gabapentin with pregabalin data (pregabalin being a closely related drug) found a modest overall pain reduction, but the gabapentin-specific evidence remains thin. In practice, pregabalin rather than gabapentin holds the FDA approval for fibromyalgia.

Chronic Low Back Pain

This is where gabapentin’s limitations become clearest. A randomized controlled trial found that gabapentin was no better than placebo for chronic low back pain, whether or not the pain radiated down the leg. Both groups saw about a 30% reduction in pain over time, meaning the improvement was likely a placebo response. The study found no meaningful relationship between gabapentin blood levels and pain intensity, and the authors concluded the drug “appears to be ineffective” for this condition. This result makes sense given that most low back pain involves muscle strain, disc problems, or joint degeneration rather than the kind of nerve injury gabapentin targets.

Perioperative and Post-Surgical Pain

Using gabapentin around the time of surgery has attracted substantial research attention, mainly because it could reduce how much opioid pain medication patients need afterward. A meta-analysis found that gabapentin cut 24-hour opioid consumption after surgery by about 35%, reduced pain both at rest and during movement, and lowered the incidence of opioid-related nausea and itching. In a trial focused on knee replacement surgery, a short course of gabapentin reduced immediate morphine use and improved early range of motion during hospital rehabilitation, though benefits disappeared by six weeks after discharge. Another large study of mixed surgical patients found that those receiving gabapentin stopped using opioids sooner after surgery, with a median time to opioid cessation of 25 days versus 32 days for controls. The perioperative context is one area where gabapentin plays a supporting role rather than serving as a standalone pain treatment.

Common Side Effects

The three side effects that come up most consistently in clinical trials are dizziness, drowsiness, and swelling of the ankles or feet. In a pooled analysis of trials in patients with postherpetic neuralgia, about 20% of those on gabapentin reported dizziness and about 15% reported drowsiness, compared with roughly 7% and 6% on placebo. Swelling was more dose-dependent: patients on 1,800 mg per day or more had a peripheral edema rate of about 7.5%, versus under 2% at lower doses or on placebo.

Neuropsychiatric side effects are less common but worth knowing about. Post-marketing surveillance suggests that roughly 29% of gabapentin users experience some form of neuropsychiatric symptom, most often dizziness, fatigue, or confusion. Less commonly, hallucinations, agitation, and aggressiveness have been reported. These reactions are generally mild to moderate, tend to be dose-dependent, and usually resolve when the dose is lowered.

The Opioid Interaction Risk

Gabapentin’s most dangerous interaction is with opioid painkillers. A large population-based study found that people prescribed both gabapentin and opioids had roughly 50% higher odds of opioid-related death after adjusting for other risk factors. The risk climbed in a dose-dependent pattern: moderate and high gabapentin doses were each associated with about a 56-58% increase in the adjusted odds of opioid-related death compared with opioid use alone. A separate study of surgical patients found that gabapentinoid use was associated with a 68% increase in the rate of respiratory complications when combined with opioids.

This creates a real clinical tension. Gabapentin is sometimes prescribed specifically to reduce opioid use after surgery, yet combining the two drugs during that transition period can increase the very respiratory risks clinicians are trying to avoid. The FDA added a warning about this in 2019, and patients taking both drugs are now advised to watch for signs of breathing difficulty, excessive sedation, or unusual drowsiness.

Misuse, Diversion, and Scheduling

Gabapentin was never classified as a controlled substance at the federal level in the U.S. That decision was based on the assumption that a drug acting on calcium channel subunits rather than opioid or benzodiazepine receptors would have low abuse potential. The reality turned out to be more complicated. Gabapentin can produce mild euphoria or sedation at high doses, and people who use opioids have found it amplifies the opioid high. Individuals with opioid use disorder, mental illness, or a history of prescription drug misuse are at the highest risk for gabapentin misuse.

In response, a growing number of U.S. states have reclassified gabapentin as a Schedule V controlled substance (the least restrictive category, the same as cough syrups containing codeine) or added it to prescription drug monitoring programs. At the federal level, however, it remains unscheduled. The practical effect is that scheduling varies dramatically depending on where you live, and some pharmacies have begun voluntarily applying stricter dispensing practices regardless of state law.

How Gabapentin Compares to Pregabalin

Pregabalin (sold as Lyrica) works through the same mechanism as gabapentin but was designed to have more predictable absorption and faster onset. A recent systematic review and meta-analysis comparing the two head-to-head for neuropathic pain found that pregabalin produced greater pain score reductions, more days with little or no pain, fewer days with severe pain, and lower opioid use. Gabapentin, on the other hand, was associated with more nausea and vomiting.

So why does gabapentin remain popular? Cost is the biggest reason. Gabapentin went generic years before pregabalin did, and even now that generic pregabalin is available, gabapentin tends to be cheaper. It also has a longer track record, and some clinicians and patients simply prefer the drug they know. For patients who respond well to gabapentin and tolerate it, there is no strong reason to switch. But for patients who have tried gabapentin without adequate relief, the meta-analytic data suggests pregabalin may be worth discussing with a prescriber.

Older Adults and Kidney Function

Gabapentin is eliminated almost entirely through the kidneys, which means the drug accumulates faster and reaches higher levels in anyone whose kidney function is reduced. Older adults are especially vulnerable because kidney function naturally declines with age, often without obvious symptoms. A population-based study found that starting gabapentin at a high dose rather than a low dose was associated with a higher risk of hospitalization with altered mental status. That risk was even more pronounced in patients with chronic kidney disease. The standard clinical recommendation is to start low and increase slowly in older adults, with dose adjustments based on kidney function.

Falls are another concern in this population. Dizziness and drowsiness, the most common side effects at any age, become more dangerous in older adults with balance problems or osteoporosis. If you’re over 65 and your doctor prescribes gabapentin, asking about renal dose adjustments and fall-prevention strategies is reasonable.

Gabapentin in Veterinary Medicine

Gabapentin has crossed over into veterinary practice as well, particularly for dogs, cats, and horses. In dogs, it has been used for epilepsy, chronic pain, post-surgical pain, and anxiety. In cats, it has shown benefit for pain after spaying and for reducing anxiety during vet visits. In horses, it is used mainly for chronic pain management. The drug’s calming properties in animals have made it especially popular as a pre-visit anxiety medication for cats, where it can make the difference between a manageable vet appointment and a chaotic one. Dosing, absorption, and duration differ across species, so veterinary gabapentin should always be prescribed by a vet rather than borrowed from a human prescription.

Stopping Gabapentin Safely

Though gabapentin is not a traditional addictive substance, physical dependence can develop with regular use. Abruptly stopping the drug after weeks or months of daily use can trigger withdrawal symptoms including anxiety, insomnia, nausea, sweating, and in rare cases seizures. This is true even in patients taking gabapentin for pain rather than epilepsy. The standard guidance is to taper the dose gradually over at least a week, though longer tapers are sometimes needed for people who have been on high doses for extended periods. Telling your doctor before stopping is important, even if you feel the drug is not helping.